Phoenix Local Business
Wednesday, July 8, 2015
PCSK9 Inhibitors: Acceptance and Appropriateness
(MedPage Today) -- Are PCSK9 inhibitors potentially appropriate for patients with mixed hyperlipidemia and high cardiovascular risk, despite statins? How will an injectable be accepted by patients? Should we wait for the CV endpoint data before use?
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment